Morgan Stanley Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $30

摩根士丹利維持10x Genomics(TXG.US)買入評級，維持目標價30美元

moomoo資訊 · 10/31 21:31 · 評級/大行評級

Morgan Stanley analyst Tejas Savant maintains $10x Genomics (TXG.US)$ with a buy rating, and maintains the target price at $30.

According to TipRanks data, the analyst has a success rate of 36.2% and a total average return of -6.7% over the past year.

AnalystRecentRatingAutoNews_77919296901262_20241031_0aa31e5c31006a4af6d3663dbda4792a9d6f493b_1730478612533885_mm_en

Furthermore, according to the comprehensive report, the opinions of $10x Genomics (TXG.US)$'s main analysts recently are as follows:

The company experienced a challenging quarter attributed to a commercial reorganization and a subdued genomics capital expenditure environment. It is anticipated that this marks the low point of the demand environment, and the organizational restructuring is expected to begin yielding moderate improvements as the demand for genomics capital expenditures starts to recover.
The projection for 10x Genomics' fiscal 2024 revenue was decreased by approximately $50M at the midpoint, suggesting that the Q4 revenue will remain constant sequentially, which falls short of the general consensus. This perceived weakness during the quarter is mainly ascribed to disruptions resulting from commercial and organizational changes, compounded by the difficult macroeconomic environment.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

摩根士丹利分析師Tejas Savant維持$10x Genomics (TXG.US)$買入評級，維持目標價30美元。

根據TipRanks數據顯示，該分析師近一年總勝率為36.2%，總平均回報率為-6.7%。

AnalystRecentRatingAutoNews_77919296901262_20241031_0aa31e5c31006a4af6d3663dbda4792a9d6f493b_1730478612533885_mm_tc

此外，綜合報道，$10x Genomics (TXG.US)$近期主要分析師觀點如下：

由於商業重組和疲軟的基因組資本支出環境，該公司經歷了一個充滿挑戰的季度。預計這標誌着需求環境的低點，隨着對基因組學資本支出的需求開始恢復，預計組織重組將開始產生適度的改善。
對10倍Genomics2024財年收入的預測在中點下降了約5000萬美元，這表明第四季度的收入將連續保持不變，未達到普遍共識。本季度這種明顯的疲軟主要歸因於商業和組織變革以及艱難的宏觀經濟環境造成的混亂。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Morgan Stanley Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $30

Morgan Stanley Maintains 10x Genomics(TXG.US) With Buy Rating, Maintains Target Price $30

風險及免責聲明

聲明